HC Wainwright Comments on Omeros' Q3 Earnings (NASDAQ:OMER)

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Omeros to a loss of $0.05 from a prior loss estimate of $0.22, while maintaining a Buy rating. The firm projects EPS of $0.24 in FY2027 and $1.63 in FY2028.
• Omeros reported quarterly EPS of $0.02, beating the consensus estimate of a $0.27 loss, while revenue of $28.53 million exceeded expectations of $12.69 million.
• Analyst sentiment remains favorable, with Omeros carrying a Moderate Buy consensus rating and an average price target of $38.00; shares recently traded near their 52-week high at $17.19.

Omeros Corporation (NASDAQ:OMER - Free Report) - Investment analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Omeros in a research report issued on Thursday, August 13th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will post earnings per share of ($0.05) for the quarter, up from their prior estimate of ($0.22). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Omeros' current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for Omeros' Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at $0.24 EPS and FY2028 earnings at $1.63 EPS.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million.

Other analysts have also issued reports about the stock. Wall Street Zen raised shares of Omeros from a "hold" rating to a "buy" rating in a research note on Saturday. Zacks Research cut Omeros from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th. Weiss Ratings upgraded Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $38.00.

Omeros Stock Performance

Omeros stock opened at $17.19 on Monday. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 13.43 and a beta of 2.54. The company's 50-day moving average price is $10.89 and its two-hundred day moving average price is $11.54. Omeros has a 52 week low of $3.94 and a 52 week high of $18.14.

Institutional Trading of Omeros

Hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wyoming bought a new stake in Omeros during the fourth quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Omeros during the 4th quarter valued at $33,000. Assetmark Inc. acquired a new stake in shares of Omeros during the 1st quarter valued at $38,000. Arax Advisory Partners boosted its stake in shares of Omeros by 56.4% during the 4th quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 1,894 shares in the last quarter. Finally, International Assets Investment Management LLC grew its holdings in shares of Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 800 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Thomas J. Cable sold 7,500 shares of the firm's stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $11.61, for a total transaction of $87,075.00. Following the completion of the transaction, the director owned 35,067 shares in the company, valued at approximately $407,127.87. This trade represents a 17.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 10.50% of the company's stock.

Key Stories Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros reported second-quarter earnings of $0.02 per share, substantially ahead of the expected $0.27 loss, while revenue of $28.53 million more than doubled the $12.69 million consensus estimate. The earnings beat was the primary catalyst for the recent advance. Omeros Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management highlighted a strong launch for YARTEMLEA, along with debt reduction and potential share repurchases. Analysts also pointed to reduced C5 competition as a favorable factor for the company’s commercial outlook. OMER Stock Soars After YARTEMLEA Momentum
• Positive Sentiment: H.C. Wainwright maintained its Buy rating and $33 price target, citing YARTEMLEA’s strong launch and a more favorable competitive environment. The target implies substantial potential upside if the commercial momentum continues. Omeros Buy Rating and $33 Price Target
• Neutral Sentiment: Omeros expanded its board from eight to nine members by appointing veteran investor Joseph Schocken. The appointment could add governance and investment expertise, but its near-term financial impact is unclear. Omeros Appoints Joseph Schocken to Board
• Neutral Sentiment: Trading in OMER call options increased sharply, indicating heightened speculative interest and bullish positioning, but options activity alone does not confirm a sustained fundamental move.
• Negative Sentiment: H.C. Wainwright lowered its long-term EPS forecasts to $3.59 for fiscal 2029 from $3.95 and to $4.62 for fiscal 2030 from $5.00. Although the firm retained its Buy rating, the revisions signal some caution about the pace of future earnings growth.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source